Deploys growth and buyout capital into software and healthcare companies across North America, emphasizing operational value creation, revenue acceleration and disciplined exit timelines. Christopher H. Gardner serves as a private equity principal and board director with experience sourcing proprietary deal flow, structuring transactions and leading portfolio company transformations. He maintains LP relationships, oversees fund economics and collaborates with management teams to scale margins and prepare assets for strategic or public sale.
Deploys growth and buyout capital into software and healthcare companies across North America, emphasizing operational value creation, revenue acceleration and disciplined exit timelines. Christopher H. Gardner serves as a private equity principal and board director with experience sourcing proprietary deal flow, structuring transactions and leading portfolio company transformations. He maintains LP relationships, oversees fund economics and collaborates with management teams to scale margins and prepare assets for strategic or public sale.
Focuses on deploying growth and buyout capital into North American software and healthcare businesses, prioritizing operational value creation, revenue acceleration and margin expansion. Combines proprietary sourcing and disciplined underwriting with hands-on portfolio operational work—restructuring go-to-market, optimizing unit economics and aligning management incentives—to drive scalable EBITDA growth and predictable exit timing. Maintains LP and board engagement to manage fund economics and execute strategic or public sale paths.
Focuses on deploying growth and buyout capital into North American software and healthcare businesses, prioritizing operational value creation, revenue acceleration and margin expansion. Combines proprietary sourcing and disciplined underwriting with hands-on portfolio operational work—restructuring go-to-market, optimizing unit economics and aligning management incentives—to drive scalable EBITDA growth and predictable exit timing. Maintains LP and board engagement to manage fund economics and execute strategic or public sale paths.
| Trades 599 | Longs Won 430/599 71% | Profit Factor 22.96 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $757,762.46 |
| Average Win $213,472.77 | Best Trade (Aug 17) $10.12M | Sharpe Ratio -21.98 |
| Average Loss -$23,661.17 | Worst Trade (Sep 01) -$462,527.88 | Z-Score 17.46 (100%) |
| Commissions $0 | Avg. Trade Length 9m | Expectancy $146,568.53 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 27,027 | 24,324 | 21,622 | 18,919 | 16,216 | 13,514 | 10,811 | 8,108 | 5,405 | 2,703 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 12,698 | $3.48M | $3.92M | - | $443,206.16 | 12.74% | -7.354% |
ABBV AbbVie Inc. | 1,441 | $325,637.98 | $361,604.54 | - | $35,966.56 | 11.04% | -2.513% |
ABT Abbott Laboratories | 2,581 | $234,224 | $272,811.7 | - | $38,587.7 | 16.47% | +0.085% |
ADP Automatic Data Processing Inc. | 1,042 | $290,156.27 | $277,651.31 | - | -$12,504.96 | -4.31% | +0.982% |
AFL Aflac Inc. | 2,448 | $273,293.15 | $312,071.04 | - | $38,777.89 | 14.19% | +0.094% |
AKBA Akebia Therapeutics Inc. | 21,038 | $56,033.32 | $27,770.16 | - | -$28,263.16 | -50.44% | -2.222% |
AMAT Applied Materials, Inc. | 1,279 | $924,717 | $649,309.94 | - | -$275,407.06 | -29.78% | +1.176% |
AMD Advanced Micro Devices, Inc. | 1,684 | $978,252 | $801,836.58 | - | -$176,415.42 | -18.03% | -1.904% |
AMZN Amazon.com Inc | 6,682 | $1.49M | $1.81M | - | $322,547.59 | 21.62% | +15.321% |
APH Amphenol Corporation | 4,662 | $247,672.5 | $374,591.7 | - | $126,919.2 | 51.24% | +0.551% |
AQST Aquestive Therapeutics Inc. | 11,000 | $45,650 | $40,645 | - | -$5,005 | -10.96% | -0.672% |
AVDE Avantis International Equity ETF | 4,368 | $379,267.24 | $398,405.28 | - | $19,138.04 | 5.05% | -0.458% |
AVDV Avantis International Small Cap Value ETF | 53,100 | $5.05M | $5.56M | - | $501,942.23 | 9.93% | -0.476% |
AVEM Avantis Emerging Markets Equity ETF | 9,891 | $783,227.63 | $885,343.41 | - | $102,115.78 | 13.04% | +0.101% |
AVGE FRCL 3 2022Q3 Hb Float | 3,629 | $359,634 | $358,508.91 | - | -$1,125.09 | -0.31% | +0.071% |
AVGO Broadcom Inc. | 1,351 | $406,147.85 | $525,917.28 | - | $119,769.43 | 29.49% | +0.371% |
AVIV Avantis International Large Cap Value ETF | 3,416 | $264,458 | $275,705.36 | - | $11,247.36 | 4.25% | -0.567% |
AVLV Avantis U.S. Large Cap Value ETF | 18,016 | $1.41M | $1.66M | - | $253,721.38 | 18.04% | +0.141% |
AVUS Avantis U.S. Equity ETF | 3,026 | $329,471.04 | $386,117.6 | - | $56,646.56 | 17.19% | +0.567% |
AVUV Avantis U.S. Small Cap Value ETF | 36,609 | $3.96M | $4.59M | - | $623,369.55 | 15.73% | +0.032% |